Sarepta Therapeutics (SRPT) Halted Ahead of FDA AdCom
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) has been halted ahead of today FDA AdCom to review the New Drug Application (NDA) for eteplirsen.
After plunging last Thursday on negative-biased FDA briefing documents, shares surged on Friday on positive draft questions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic PBC: adjusted operating income increased for the three months ended September 30, 2026 to $2.5 billion
- Okta to join S&P 500
- Pakistan military 'cautiously optimistic' on Iran-U.S. mediation - Reuters
Create E-mail Alert Related Categories
FDA, Trader Talk, Trading HaltsRelated Entities
AdComSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
